View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

DXP Enterprises Reports Fourth Quarter and Fiscal 2024 Results

HOUSTON--(BUSINESS WIRE)-- DXP Enterprises, Inc. (NASDAQ: DXPE) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. The following are results for the three and twelve months ended December 31, 2024, compared to the three and twelve months ended December 31, 2023. A reconciliation of the non-GAAP financial measures can be found in the back of this press release. Fourth Quarter 2024 financial highlights: Sales were $470.9 million for the fourth quarter of 2024, compared to $407.0 million for the fourth quarter of 2023. Diluted earnings per share...

 PRESS RELEASE

DXP Enterprises, Inc. Announces Fourth Quarter and FY2024 Earnings Rel...

HOUSTON--(BUSINESS WIRE)-- DXP Enterprises, Inc. (the “Company”) (NASDAQ: DXPE), a leading business to business products and service distributor that adds value and total cost savings solutions to MRO and OEM customers in virtually every industry, plans to issue a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024, on Thursday, March 6th. The earnings announcement will be released after the market closes. DXP will host a conference call, to be web cast live, on the Company’s website () at 10:30 AM Central Time on Friday, March 7th. Th...

 PRESS RELEASE

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and ...

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated. As a result, the board of directors will reassess the Company’s strategic alternatives, including out-licensing, merger and acquisition opportunities (including reverse mergers), the sale of assets and technologies, and winding down operations, among o...

 PRESS RELEASE

Seneca Foods Reports Sales and Earnings for the Quarter and Nine Month...

Seneca Foods Reports Sales and Earnings for the Quarter and Nine Months Ended December 28, 2024 FAIRPORT, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Seneca Foods Corporation (NASDAQ: SENEA, SENEB) today announced financial results for the third quarter and nine months ended December 28, 2024. Executive Summary (vs. year-ago, year-to-date results): Net sales for the nine months ended December 28, 2024 totaled $1,233.0 million compared to $1,150.6 million for the nine months ended December 30, 2023. The year-over-year increase of $82.4 million was due mainly to higher sales v...

 PRESS RELEASE

DXP Enterprises, Inc. Announces Acquisition of Arroyo Process Equipmen...

HOUSTON--(BUSINESS WIRE)-- DXP Enterprises, Inc. (NASDAQ: DXPE) today announced that it has completed the acquisition of Arroyo Process Equipment (“Arroyo”). Founded in 1968, Arroyo is headquartered in Bartow, Florida and operates out of three locations servicing northern, central, and southern Florida, and surrounding markets. Arroyo is a leading distributor of pumps, process equipment, and related service and repairs focused on serving the asphalt, mining, industrial water, chemical and other industrial markets. DXP funded the acquisition with cash from the balance sheet. “We are pleased...

 PRESS RELEASE

Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqor...

Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 Companies also provide insights into proposed strategic merger SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data f...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Vincerx Pharma, Inc. Announces Reverse Stock Split

Vincerx Pharma, Inc. Announces Reverse Stock Split Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which will be effective as of January 27, 2025 at 4:01 p.m., Eastern Time. Vincerx’s common stock will cont...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols bymarket-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 28, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger...

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1...

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 Also Exploring Strategic Alternatives to Complement Fundraising Efforts PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the Company’s novel CD123-targeted antibody-drug conjugate (ADC) developed with the Company’s ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch